← Leaderboards
Arun Rajan
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
- Udayan Guha$0
- Giuseppe Giaccone$330,044
- Daniel Edelman$0
- Chuong Hoang$0
- Ravi Madan$0
Others in their field
Top investigators on “Enrollment”
- Jeffrey P Krischer · University Of South Florida$370,021,822
- Lawrence Corey · Fred Hutchinson Cancer Center$329,293,433
- David R. Weir · University Of Michigan At Ann Arbor$265,368,888
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$231,949,330
- James Dennis Neaton · Northwestern University$218,104,551
- George R Seage · Abt Associates, Inc.$205,403,788
Research focus
EnrollmentResponseRecurrenceObjective Response RateNon-Small-Cell Lung CarcinomaThymic CarcinomaSafetyPartial ResponseTumorAdverse EventImmunotherapyEvaluable DiseaseProgrammed Cell Death Ligand 1CohortClinical TrialsProgression-Free SurvivalsPhase Ii TrialThymomaRelapseRefractoryDoseSolid NeoplasmImmune-Related Adverse EventsMeetings
Grant awards (53)
Medical Oncology Service Clinical Core$4,245,233
ZID · FY2025 · CA · contact PI
Medical Oncology HIV-AIDS Clinical Research$749,159
ZID · FY2025 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$530,186
ZIA · FY2025 · CA · contact PI
A Phase II Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma$477,167
ZIA · FY2025 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$353,458
ZIA · FY2025 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$176,728
ZIA · FY2025 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced Non-Small Cell Lung Cancer$176,728
ZIA · FY2025 · CA · contact PI
Anetumab in Thymic Carcinoma$35,345
ZIA · FY2025 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$17,673
ZIA · FY2025 · CA · contact PI
Medical Oncology Service Clinical Core$2,885,087
ZID · FY2024 · CA · contact PI
Medical Oncology HIV-AIDS Clinical Research$509,133
ZID · FY2024 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$489,473
ZIA · FY2024 · CA · contact PI
A Phase II Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma$440,525
ZIA · FY2024 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$326,315
ZIA · FY2024 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$163,158
ZIA · FY2024 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced Non-Small Cell Lung Cancer$163,158
ZIA · FY2024 · CA · contact PI
Anetumab in Thymic Carcinoma$32,631
ZIA · FY2024 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$16,316
ZIA · FY2024 · CA · contact PI
Medical Oncology Service Clinical Core$2,842,329
ZID · FY2023 · CA · contact PI
Medical Oncology HIV-AIDS Clinical Research$501,587
ZID · FY2023 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$397,910
ZIA · FY2023 · CA · contact PI
A Phase II Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma$358,119
ZIA · FY2023 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$265,273
ZIA · FY2023 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer$132,637
ZIA · FY2023 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$132,637
ZIA · FY2023 · CA · contact PI
Anetumab in Thymic Carcinoma$26,527
ZIA · FY2023 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$13,264
ZIA · FY2023 · CA · contact PI
Medical Oncology Service Clinical Core$3,662,007
ZID · FY2022 · CA · contact PI
Medical Oncology HIV-AIDS Clinical Research$646,236
ZID · FY2022 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$297,969
ZIA · FY2022 · CA · contact PI
A Phase II Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma$268,172
ZIA · FY2022 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$198,645
ZIA · FY2022 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$99,323
ZIA · FY2022 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer$99,323
ZIA · FY2022 · CA · contact PI
Anetumab in Thymic Carcinoma$19,865
ZIA · FY2022 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$9,932
ZIA · FY2022 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$505,068
ZIA · FY2021 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$202,027
ZIA · FY2021 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$101,013
ZIA · FY2021 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer$101,013
ZIA · FY2021 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$50,506
ZIA · FY2021 · CA · contact PI
Anetumab in Thymic Carcinoma$50,506
ZIA · FY2021 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$648,020
ZIA · FY2020 · CA · contact PI
Anetumab in Thymic Carcinoma$194,406
ZIA · FY2020 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$129,604
ZIA · FY2020 · CA · contact PI
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma$129,604
ZIA · FY2020 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer$129,604
ZIA · FY2020 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$64,802
ZIA · FY2020 · CA · contact PI
Pilot Study of Avelumab in Thymic Epithelial Tumors$35,123
ZIA · FY2019 · CA · contact PI
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer$14,050
ZIA · FY2019 · CA · contact PI
Anetumab in Thymic Carcinoma$10,537
ZIA · FY2019 · CA · contact PI
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer$7,024
ZIA · FY2019 · CA · contact PI
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer$3,513
ZIA · FY2019 · CA · contact PI